Home > News > Top Stories > Massive Bio and Datavant Expand Partnership to Integrate Datavant’s Medical Record Retrieval Capabilities to Revolutionize Patient Care

Digital Healthcare, Medical Devices

Massive Bio and Datavant Expand Partnership to Integrate Datavant’s Medical Record Retrieval Capabilities to Revolutionize Patient Care

Massive Bio, a leader in leveraging artificial intelligence and concierge services to empower cancer patients, and Datavant, the leader in helping organizations securely connect data, are thrilled to announce an expanded partnership that leverages Datavant’s national scale in medical record retrieval and Massive Bio’s expertise in AI-driven clinical trial matching to accelerate clinical research and improve patient care in cancer.

This expanded partnership builds upon an earlier pilot that enabled Massive Bio to request, retrieve, and digitally deliver clinical data with higher reliability, faster speed and greater coverage across sites of care, thus significantly improving patient outcomes while ensuring compliance and data privacy.

Massive Bio's CEO, Selin Kurnaz, emphasizing the significance of this partnership states, "By integrating Datavant's cutting-edge technology, we are making a leap in the provision of personalized cancer treatments. This collaboration empowers us to access patient medical records for any patient in the country in a scalable, secure and compliant manner, thereby accelerating our ability to provide data-driven, personalized care."

Dr. Arturo Loaiza-Bonilla, Co-Founder and Chief Medical Officer at Massive Bio, adds, "By leveraging the Datavant Switchboard, we are strategically positioned to drive meaningful cost savings while improving patient care. Especially for our oncology patients, the ability to obtain complete clinical histories from the medical record would be a challenge. We are thrilled to be working with Datavant, whose national scale of data connectivity can help us access full medical records, including unstructured data, that is essential to our work. Datavant is transforming how clinical data is used and shared, ultimately bringing us closer to achieving our mission of providing the right treatment to the right patient at the right time."

"We are excited about this partnership with Massive Bio. Their innovative approach to personalized cancer care aligns with our mission of securely connecting health data to improve patient outcomes," says Tal Rosenberg, President, Emerging Businesses & Chief Partnerships Officer at Datavant. "This collaboration not only marks a significant step forward in patient care but also emphasizes our shared commitment to reducing friction and increasing security in health data exchange."

With this expanded partnership, Massive Bio will integrate Datavant’s medical record retrieval capabilities into Massive Bio’s operations in order to expedite the identification of potential clinical trial participants and speed up time to insight in clinical research.

About Datavant

Datavant's mission is to connect the world's health data to improve patient outcomes. Datavant works to reduce the friction of data sharing across the healthcare industry by building technology that protects the privacy of patients while supporting the linkage of patient health records across datasets.

About Massive Bio

Massive Bio is at the forefront of empowering cancer patients to discover their optimal treatment options. Utilizing AI to enhance equitable access and precision targeting for clinical trial matching, drug matching, and drug development, Massive Bio is committed to breaking down barriers in clinical trial enrollment, fostering value-based oncology decisions, and facilitating data-driven cancer treatment. Serving over three dozen pharmaceutical companies, contract research organizations, and hospital networks, Massive Bio has earned recognition from the National Cancer Institute with an SBIR contract. Founded in 2015 by a team of clinical, technology, and M&A executives, Massive Bio boasts a global presence with nearly 100 people across 12 countries.

Spotlight

More featured news

Spotlight

Related News

Health Technology, Digital Healthcare

GE HealthCare and Novo Nordisk to Collaborate to Advance Novel Non-Invasive Treatment for Type 2 Diabetes and Obesity with Ultrasound

Business Wire | October 20, 2023

GE HealthCare announced a collaboration with Novo Nordisk to further advance the clinical and product development of peripheral focused ultrasound (PFUS). This is a novel technology that has potential to specifically regulate metabolic function in the body using ultrasound that may support the treatment of chronic diseases such as type 2 diabetes and obesity. PFUS is a non-invasive type of bioelectronic medicine that uses ultrasound to activate the nervous system to stimulate a response that may be able to treat disease. Pre-clinical proof of concept and initial early-stage clinical research suggests that it may impact glucose metabolism in people with diabetes via personalized ultrasound stimulation of nerve pathways. If validated with further clinical evidence, PFUS could represent a non-pharmacologic approach to normalize blood glucose levels in people with type 2 diabetes. The existing technology was developed by a team of scientists at GE HealthCare’s HealthCare Technology and Innovation Center, formerly part of the GE Research Center. said Roland Rott, President and CEO, Ultrasound, GE HealthCare. In an era where diabetes is increasing around the globe, we are enthusiastic about the potential for ultrasound to help people live healthier lives, This collaboration with Novo Nordisk opens a path to evolve ultrasound from a means of screening and diagnosis into therapy, as well. We are eager to validate and further develop this potentially groundbreaking science, as we strive to offer patients alternative treatment options for chronic diseases. [Source – Business Wire] An estimated 540 million adults around the world have diabetes, with type 2 diabetes accounting for more than 90 percent of cases.1 An estimated one in eight individuals will have diabetes in 2045, with significant disease burden in low-and-middle-income countries.1 Given its impact on quality of life and mortality, and with its prevalence increasing at an alarming rate for the past three decades,2 type 2 diabetes is a significant public health burden. Obesity impacts approximately 1 billion people worldwide.3 “We look forward to exploring the potential impact this technology could have on treating people with type 2 diabetes and obesity, as significant unmet needs remain in these diseases in spite of recent advances in care,” said Martin Holst Lange, Executive Vice President and Head of Development at Novo Nordisk. “Although early, the possibilities of using ultrasound for therapeutic purposes are compelling and we welcome our collaboration with GE HealthCare in this truly novel area.” As part of the collaboration, GE HealthCare and Novo Nordisk will contribute their respective expertise in ultrasound medical technology and metabolic disease treatment and management as both parties work together to develop a PFUS solution to improve patient care, building upon the extensive foundational research done to date by the GE HealthCare team. Additional terms of the agreement were not disclosed. About GE HealthCare Technologies Inc. GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 100 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient’s journey across the care pathway. Together our Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from diagnosis, to therapy, to monitoring. We are an $18.3 billion business with 50,000 employees working to create a world where healthcare has no limits.

Health Technology, AI

Atrium Health's AI Solution Improves Documentation of Most Physicians

Atrium Health's | October 11, 2023

The collaboration between Atrium Health and Nuance in introducing this solution was presented at the 2023 HLTH Conference held in Las Vegas. Atrium Health clinicians strongly support DAX, with 92% finding it easy to use, 85% valuing DAX Copilot access, 84% reporting better documentation, and 68% improving care delivery. Atrium Health excels in pediatrics, cancer, heart care, organ transplants, burn treatments, and specialized musculoskeletal programs while leading in virtual care and mobile medicine innovations. Atrium Health's clinical leaders have embraced a fundamental concept called the 'Best Place to Care.' As an integral component of this initiative, the company conducts comprehensive surveys among its healthcare providers to gain insights into enhancing their job satisfaction and mitigating the risk of burnout. The company has achieved the distinction of being a pioneering health system in implementing an AI tool known as Nuance Dragon Ambient eXperience Copilot (DAX Copilot), specifically designed to streamline the generation of clinical documentation during patient consultations. This innovative technology is pivotal in liberating healthcare practitioners from administrative tasks, allowing them to direct their undivided attention toward delivering personalized, high-quality patient care. It also enhances the overall efficiency of clinical processes and mitigates the workload associated with administrative responsibilities, which often contribute to healthcare provider burnout. Dr. Matthew Anderson, Senior Vice President and Medical Director of Virtual Health for Advocate Health and Atrium Health's Senior Medical Director for Primary Care, stated, "In addition to providing high-quality patient experiences and elevating clinical efficiency, supporting clinician satisfaction and retention by enabling physicians and nurses to work at the top of their licensure is one of our top organizational priorities." He further added, DAX Copilot is enabling a better clinician experience. Most of our surveyed users are reporting a positive impact on their day-to-day schedule, being able to increase the number of patients they are able to see and even spending more time with them. This type of scale and satisfaction is critical in the advancement of healthcare. [Source – Cision PR Newswire] Atrium Health has utilized DAX Copilot among its primary care physicians, with extensive deployment plans encompassing its operational domain. This innovative solution empowers clinicians to swiftly and securely generate preliminary clinical summaries in mere seconds, derived from in-person examinations or telehealth interactions, enabling immediate review and finalization within the Electronic Health Record (EHR) system. Notably, Atrium Health's physicians have already communicated substantial time savings of up to 40 minutes per day attributed to the adoption of this advanced documentation assistant. DAX Copilot, an evolution of Dragon's ambient technology used by thousands of clinicians, has delivered significant benefits: a 70% reduction in burnout, 50% less time on documentation, saving seven minutes per patient encounter, and adding an average of five appointments per clinic day. It's a user-friendly gateway for healthcare organizations to embrace advanced AI-driven clinical documentation, building upon their Nuance Dragon Medical platform investments with over 550,000 users. In a private preview of DAX Copilot, clinicians reported improved work-life balance, higher job satisfaction, more engaging patient interactions, and reduced burnout.

Healthcare Analytics

GE HealthCare Releases Sustainability Report, Shares Future Goals

GE HealthCare | September 25, 2023

First Sustainability Report since January 2023 showcases the company’s commitment to creating a world with no healthcare limits Report shows reduced operational Scope 1 and 2 greenhouse gas emissions by 27% since 2019 Strong leadership focus on sustainability efforts and ESG with a cross-functional ESP GE HealthCare has released its inaugural Sustainability Report, marking its commitment to environmental, social, and governance (ESG) practices since becoming an independent company in January 2023. The report highlights the reduction of operational Scope 1 and 2 greenhouse gas emissions by 27% since 2019 and outlines the company's dedication to ESG principles and sustainability. GE HealthCare recognizes the importance of sustainability and corporate responsibility in the healthcare industry. The report reflects the company's dedication to creating a world where healthcare knows no limits and its commitment to environmental and social impact. ESG Program Leader at GE HealthCare, Kelvin Sanborn, stated, GE HealthCare recognizes the global significance of fulfilling our purpose and delivering on our objectives and is pleased to have reduced our operational GHG emissions by 27% versus our 2019 baseline. With our broad ESG strategy and priorities in mind, we are carrying out a climate risk assessment that will inform our climate transition plan, and developing a net zero roadmap for Scope 1, 2, and 3 GHG emissions. [Source: Business Wire] Key Highlights from the Company's Inaugural Sustainability Report: Environmental Impact Since 2019, reduced GHG emissions by 27% with goals of 50% reduction by 2030 and net zero by 2050 Registered with Science Based Targets Initiative Committed to decarbonizing the healthcare sector Social Impact Established cultural operating principles Planned GE Healthcare Foundation for philanthropy Appointed chief diversity, equity, and inclusion officer Governance and Accountability Strong corporate governance as a stand-alone public company Relaunched Code of Conduct with high employee engagement Joined UN Global Compact to support sustainable development goals GE HealthCare conducted an ESG materiality assessment, defining five key focus areas for its sustainability strategy. These include expanding healthcare access, fostering diversity and inclusion, reducing greenhouse gas emissions, promoting the circular economy, and enhancing patient data cybersecurity. The report outlines the company's long-term ESG objectives and progress toward previous goals. It is preparing to release an updated task force on climate-related financial disclosures (TCFD) report once its climate risk assessment is finalized. Furthermore, the company has scheduled a materiality assessment update for 2024. In parallel, GE HealthCare is exploring the expansion of Reporting Standards for its ESG disclosures and evaluating how its objectives align with the United Nations Sustainable Development Goals (UN SDGs). After conducting an ESG materiality assessment before its spin-off, the company has pinpointed five vital areas for its sustainability strategy. These priorities, underscored by the company's core innovation, product quality, and integrity principles, encompass the following: Expanding global healthcare access by ensuring underserved populations have better healthcare opportunities; promoting a culture of inclusion and diversity; mitigating its climate impact through concerted efforts; facilitating equipment and prioritizing patient data security and cybersecurity by adhering to standardized data privacy and security practices based on global regulations such as the EU GDPR.